Labiotech.eu

karolinska development akinion acute myeloid leukemia aml liver toxicity phase II akn 028 tyrosine kinase inhibitor

News and Trends 7 Mar 2016

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Akinion (Sweden) will stop the development of its candidate for leukemia, after patients in phase I/II have experienced liver toxicity. As a result, main investor Karolinska Development takes an €8M hit in its portfolio valuation. Sad news for Akinion. This Stockholm-based drug developer decided to halt the development of its lead candidate, APN-028. This happens after […]

March 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

crispr mimivire aix nature virus synbio biotech

News and Trends 4 Mar 2016

This Megavirus has its own CRISPR-like Defense System

MIMIVIRE is the name French researchers have given to the immunity mechanism of mimivirus, and that they have now described in a new paper for Nature. What is a mimivirus? What is viral immunity? What is life? What is CRISPR? Well, for the last question, you should read our review on CRISPR. As for the rest, […]

March 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

horizon centarui axxinity venture therapeutics alphamers cancer1

News and Trends 4 Mar 2016

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Merck (Germany) has initiated a phase III trial for a biosimilar of AbbVie’s Humira, to treat Chronic plaque psoriasis. This is a big deal as Humira is the best selling biologics of all time (over €10Bn in annual revenues). Merck is developing a candidate (MSB11022) as a biosimilar of adalimumab, a human monoclonal antibody sold under the brand Humira – a key […]

March 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 4 Mar 2016

Biotech of the week: Solvo, an Efficient Drug Transportation Solution in Hungary

This week, we leave the charming landscapes of southern France and head up to the East. In Budaörs, a suburban city located near Budapest, Hungary’s capital, is where SOLVO, our Biotech of the Week, is located. City: Budders (Budapest), Hungary Founded: 1999 Employees: 80 Financial Data: N/A CEO: Ernő Duda Mission: Solvo Biotechnology’s line of work focuses on the […]

March 4, 2016 - 2 minutesmins - By Joachim Eeckhout

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

RedHill Biopharma (Israel) is in a solid financial position to reap the benefits of several advanced trials in inflammatory gastrointestinal diseases, including Crohn’s. The company just released its financial statements, with some interesting highlights… Based in Tel-Aviv, RedHill is developing small molecule oral drugs for a variety of conditions connected to the gastrointestinal tract. It is listed […]

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

autism spectrum disorder seaside therapeutics asd fragile x biotech

News and Trends 3 Mar 2016

Reviewing Autism: Can Biotech open up New Horizons?

While Autism Spectrum Disorders (ASD) affect approximately one in 68 children, this hasn’t provoked much enthusiasm among pharmaceutical companies to develop drugs. However, recent advances in basic research Autism and novel gene-editing technologies may boost ASD drug development. The reasons for low interest are a poor understanding of the biological mechanisms underlying Autism Spectrum Disorder, the […]

March 3, 2016 - 6 minutesmins - By Ekaterina Perets

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

win horizon centauri antibody avvinity cancer alphamer

News and Trends 2 Mar 2016

New Joint Venture to Shake Up Immuno-Oncology in the UK

Avvinity Therapeutics is the new child of two UK Biotechs: Horizon Discovery and Centauri. The goal? To create the ultimate immuno-oncology toolbox with€32M. Just created, Avvinity is a joint venture targeting the immuno-oncology field, which is worth around €32M – and is only expected to grow. The biotechnological approach to cancer treatments has many Pharma and Biotech companies interested, […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

syngenta hong kong china monsanto biotech agribusiness

News and Trends 2 Mar 2016

Chinese Chemical Giant moves closer to buy Swiss Syngenta for €39.5Bn

Following Monsanto’s failed second attempt to merge with Syngenta, the Chinese seems to have better luck swaying this European chemical giant. Now ChemChina has its looking to secure a multi-billion loan facility for the acquisition. Syngenta is a well known agribusiness leader in agriculture and seeds production. This Swiss agro-tech was born in 2000 after the merger […]

March 2, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 1 Mar 2016

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Carmat (France) has raised €50M from private investors (dwarfing its 2015’s €3M reserves) in order to further develop its artificial hearts during 2016 and apply for CE Marking. This French Medtech company is developing an artificial heart (one of top examples of futuristic cyborg-like technologies in biotech) that could help patients with end-stage biventricular heart failure. There are people […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Swedish Investment loses €8M over failed Phase I/II for Leukemia

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

This Megavirus has its own CRISPR-like Defense System

The Best Selling Biologic of All Time now chased by New Phase III Biosimilar

Biotech of the week: Solvo, an Efficient Drug Transportation Solution in Hungary

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

Reviewing Autism: Can Biotech open up New Horizons?

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

New Joint Venture to Shake Up Immuno-Oncology in the UK

Chinese Chemical Giant moves closer to buy Swiss Syngenta for €39.5Bn

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!